NL300144I2 - 20-Spiroxanen en analoga met geopende ring E, werkwijzen ter bereiding ervan, alsmede farmaceutsche preparaten ervan. - Google Patents

20-Spiroxanen en analoga met geopende ring E, werkwijzen ter bereiding ervan, alsmede farmaceutsche preparaten ervan.

Info

Publication number
NL300144I2
NL300144I2 NL300144C NL300144C NL300144I2 NL 300144 I2 NL300144 I2 NL 300144I2 NL 300144 C NL300144 C NL 300144C NL 300144 C NL300144 C NL 300144C NL 300144 I2 NL300144 I2 NL 300144I2
Authority
NL
Netherlands
Prior art keywords
spiroxanes
analogues
processes
preparation
pharmaceutical preparations
Prior art date
Application number
NL300144C
Other languages
English (en)
Dutch (nl)
Other versions
NL300144I1 (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL300144I1 publication Critical patent/NL300144I1/nl
Publication of NL300144I2 publication Critical patent/NL300144I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL300144C 1983-04-13 2004-03-25 20-Spiroxanen en analoga met geopende ring E, werkwijzen ter bereiding ervan, alsmede farmaceutsche preparaten ervan. NL300144I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
NL300144I1 NL300144I1 (nl) 2004-06-01
NL300144I2 true NL300144I2 (nl) 2004-06-01

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300144C NL300144I2 (nl) 1983-04-13 2004-03-25 20-Spiroxanen en analoga met geopende ring E, werkwijzen ter bereiding ervan, alsmede farmaceutsche preparaten ervan.

Country Status (23)

Country Link
US (1) US4559332A (OSRAM)
EP (1) EP0122232B1 (OSRAM)
JP (1) JPS59231100A (OSRAM)
AR (4) AR241918A1 (OSRAM)
AT (1) ATE39256T1 (OSRAM)
AU (1) AU565017B2 (OSRAM)
CA (1) CA1220781A (OSRAM)
DD (2) DD233375A5 (OSRAM)
DE (2) DE3475622D1 (OSRAM)
DK (1) DK163988C (OSRAM)
ES (4) ES8602846A1 (OSRAM)
FI (1) FI77669C (OSRAM)
GR (1) GR81834B (OSRAM)
HU (1) HU191406B (OSRAM)
IE (1) IE57541B1 (OSRAM)
IL (1) IL71504A (OSRAM)
LU (1) LU91072I2 (OSRAM)
NL (1) NL300144I2 (OSRAM)
NO (1) NO159800C (OSRAM)
NZ (1) NZ207826A (OSRAM)
PH (1) PH19997A (OSRAM)
PT (1) PT78413B (OSRAM)
ZA (1) ZA842710B (OSRAM)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
ES2115665T3 (es) * 1991-01-29 1998-07-01 Shionogi & Co Derivado de triterpeno.
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
RU2166330C2 (ru) * 1995-06-07 2001-05-10 Джи. Ди. Сирл Энд Ко. Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
EA009176B1 (ru) * 1995-12-11 2007-12-28 Дж.Д.Серл Энд Ко. Способ получения 7-альфа-карбоксил-9,11-эпоксистероидов и промежуточных продуктов, используемых для их получения, и общий способ эпоксидирования по олефиновым двойным связям
EP1167380A3 (en) * 1995-12-11 2004-12-08 G.D. Searle & Co. 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
EP0944644B1 (en) * 1996-12-11 2002-10-02 G.D. Searle & Co. PROCESSES FOR PREPARATION OF 3-KETO-7alpha-ALKOXYCARBONYL-delta-4,5- STEROIDS AND INTERMEDIATES USEFUL THEREIN
US6368835B1 (en) * 1998-05-29 2002-04-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing a lactone using corynebacterium sp. NK-1 (FERM BP-6329)
KR20010100986A (ko) * 1998-11-06 2001-11-14 로저 에이. 윌리암스 심장혈관 질병으로 인한 이병률 및 사망률 감소용안지오텐신 전환 효소 억제제 및 알도스테론 길항제의결합 치료방법
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
IL143944A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
CA2356240C (en) 1998-12-23 2008-04-01 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
DE69904079T2 (de) 1998-12-23 2003-07-17 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
ES2201822T3 (es) * 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
WO2000038724A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
PT1175220E (pt) * 1999-12-08 2005-07-29 Pharmacia Corp Composicoes de eplerenona em nanoparticulas
BR0008054A (pt) * 1999-12-08 2002-03-12 Pharmacia Corp Forma cristalina de eplerenona
WO2001042272A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2001261434A1 (en) * 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
JP2004511435A (ja) * 2000-07-27 2004-04-15 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とβ−アドレナリン作動性拮抗薬の併用療法
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
CN1531590A (zh) * 2000-10-30 2004-09-22 赭曲霉11α-羟化酶和氧化还原酶
MXPA03004112A (es) * 2000-11-09 2003-08-19 Astrazeneca Ab Composicion farmaceutica oral que contiene un copolimero de bloque.
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
EP1448546A4 (en) * 2001-11-02 2005-02-02 Searle Llc MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF TRANSPORT OF ACIDICALLY DEPENDENT SODIUM ACILIC (ASBT) BILIARY ACIDS AND TAUROCHOLATE RECOVERY
EP1455795A1 (en) 2001-12-12 2004-09-15 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
MXPA04009039A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de los receptores de la aldosterona y un agente secuestrante de los acidos biliares.
PL373032A1 (en) * 2002-03-18 2005-08-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
MXPA04009037A (es) * 2002-03-20 2005-01-25 Pharmacia Corp Formulacion de eplerenona de almacenamiento estable.
DK1487859T3 (da) * 2002-03-22 2008-10-06 Pharmacia & Upjohn Co Llc Fremstillingsmetoder til at fremstille Eplerenon
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
AU2003285485A1 (en) * 2002-08-16 2004-03-03 Pharmacia & Upjohn Company Llc 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
RU2304144C2 (ru) * 2002-11-06 2007-08-10 Фармация Энд Апджон Компани Ллс 7-карбоксизамещенные стероиды, способ их получения, способы получения эплеренона
HK1080088A1 (zh) * 2002-11-07 2006-04-21 法马西亚和厄普乔恩公司 制备c-7取代的5-雄甾烯的方法
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
TW200602352A (en) * 2004-03-22 2006-01-16 Upjohn Co Improved process for the preparation of 9,11 epoxy steroids
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
US20100086586A1 (en) * 2006-12-21 2010-04-08 Brett Antony Mooney Pharmaceutical Composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ES2602902T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
UY32660A (es) 2009-05-28 2010-12-31 Novartis Ag Derivados aminobutricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011097571A2 (en) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
MA38330B1 (fr) 2013-02-14 2016-09-30 Novartis Ag Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
NO841465L (no) 1984-10-15
AR242221A1 (es) 1993-03-31
FI77669B (fi) 1988-12-30
PT78413A (en) 1984-05-01
FI77669C (fi) 1989-04-10
NL300144I1 (nl) 2004-06-01
IE840906L (en) 1984-10-13
NZ207826A (en) 1986-07-11
GR81834B (OSRAM) 1984-12-12
HU191406B (en) 1987-02-27
LU91072I2 (fr) 2004-04-07
AU2685384A (en) 1984-10-18
DK189484D0 (da) 1984-04-12
EP0122232A1 (de) 1984-10-17
DE122004000012I2 (de) 2006-06-08
ES531517A0 (es) 1985-12-01
FI841400L (fi) 1984-10-14
ES544770A0 (es) 1987-05-01
IE57541B1 (en) 1992-10-07
US4559332A (en) 1985-12-17
IL71504A (en) 1987-07-31
ZA842710B (en) 1984-11-28
DE122004000012I1 (de) 2012-05-16
DD251144A5 (de) 1987-11-04
DD233375A5 (de) 1986-02-26
ES8705459A1 (es) 1987-05-01
ES8705461A1 (es) 1987-05-01
ATE39256T1 (de) 1988-12-15
AR242222A1 (es) 1993-03-31
AR242223A1 (es) 1993-03-31
JPS59231100A (ja) 1984-12-25
AR241918A1 (es) 1993-01-29
ES544769A0 (es) 1987-05-01
NO159800B (no) 1988-10-31
AU565017B2 (en) 1987-09-03
EP0122232B1 (de) 1988-12-14
ES8602846A1 (es) 1985-12-01
FI841400A0 (fi) 1984-04-09
CA1220781A (en) 1987-04-21
DE3475622D1 (en) 1989-01-19
NO159800C (no) 1989-02-08
JPH0212479B2 (OSRAM) 1990-03-20
DK163988B (da) 1992-04-27
PH19997A (en) 1986-08-28
DK189484A (da) 1984-10-14
ES544768A0 (es) 1987-05-01
IL71504A0 (en) 1984-07-31
ES8705460A1 (es) 1987-05-01
DK163988C (da) 1992-09-21
PT78413B (en) 1986-08-22

Similar Documents

Publication Publication Date Title
NL300144I2 (nl) 20-Spiroxanen en analoga met geopende ring E, werkwijzen ter bereiding ervan, alsmede farmaceutsche preparaten ervan.
FI872652A7 (fi) Hidasluovutteiset farmaseuttiset valmisteet.
FI843773A7 (fi) Menetelmä sellaisten pitkitetyn vaikutuksen omaavien farmaseuttisten v almisteiden valmistamiseksi, joissa on korkea aktiivisen aineosan pito isuus.
NO874038L (no) Fortykkede vandige rengjoeringspreparater.
FI802079A7 (fi) Uudet syklopeptidit ja niistä tehdyt farmaseuttiset valmisteet, sekä menetelmä niiden valmistamiseksi.
NL194578B (nl) Farmaceutisch preparaat met cyclosporine.
IT8467535A1 (it) Preparazioni farmaceutiche aventi ridotta tossicità.
FI874596L (fi) Peptidpreparat.
FI873630A7 (fi) Stabilt farmaceutiskt preparat.
IT8721411A0 (it) Composizione farmaceutica idrosolubile contenente n acetilsisteina.
FI824419A7 (fi) Sykliset oktapeptidit ja niiden farmaseuttiset valmisteet, sekä menetelmä niiden valmistamiseksi ja niniiden käyttö.
IT8721410A0 (it) Composizione farmaceutica idrosolubile contenente n acetilcisteina.
FI873798A7 (fi) Aminoglykosidisteroideja, menetelmä niiden valmistamiseksi, niiden käy ttö sekä niitä sisältävät farmaseuttiset seokset.
NO862439D0 (no) Farmasoeytiske preparater.
FI874382A7 (fi) Farmaseuttiset valmisteet.
FI832291A7 (fi) Ditio-yhdisteet, menetelmä niiden valmistamiseksi, niitä sisältävät farmaseuttiset valmisteet, ja niidenkäyttö.
FI873799A7 (fi) Aminoglykosidisteroideja, menetelmä niiden valmistamiseksi, niiden käy ttö sekä niitä sisältävät farmaseuttiset seokset.
FI834138A7 (fi) Heterosyklyyliyhdisteet, menetelmä niiden valmistamiseksi, näitä yhdisteitä sisältävät farmaseuttiset valmisteet sekä niiden käyttö.
DE3380989D1 (de) 2-aminobenzosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen.
FI875616A0 (fi) Farmaceutiska blandningar.
FI803846A7 (fi) Farmaseuttiset valmisteet.
FI834140A7 (fi) Heterosyklyylitioyhdisteet, menetelmä niiden valmistamiseksi, näitä yhdisteitä sisältävät farmaseuttiset valmisteet sekä niiden käyttö.
FI830617A7 (fi) 1,4-dihydropyridiini-johdannaiset, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet.
FI853368A7 (fi) Uusia pseudo-oligosakkarideja, joilla on -glukosidaasia estävä vaikutus, menetelmä niiden valmistamiseksi, niiden käyttö ja farmaseuttisia valmisteita.
FI873483A7 (fi) Oksiraanipseudo-oligosakkarideja, menetelmä niiden valmistamiseksi, niiden käyttö ja farmaseuttisia valmisteita.